The antibody component of<unk>  binds to CD22 receptors, which are expressed mostly on B cells. The whole conjugate is then drawn into the cell, where the ozogamicin is cleaved from the antibody by the acidic environment of the lysosome. The ozogamicin eventually travels to the nucleus where it breaks up DNA, causing the cell to die.
Inotuzumab ozogamicin
Ranibizumab
Gemtuzumab ozogamicin
Bevacizumab
Ponatinib
Sorafenib
Ruxolitinib
Erdafitinib